TrialPloS one2013

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

George Fountzilas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.